AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🌍 Showing

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Condition

Country

City (shown first)

24 recruiting trials

for Hepatitis B, Chronic (CHB)

SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus NCT06364930Phase 41 site📍 Hong Kong Chinese University of Hong Kong · Tests: Dapagliflozin 10mg Tab, Placebo 10mg Tab Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study） NCT06323681NA1 site📍 Shanghai Qing XIe · Tests: Peginterferon α-2b based treatment group, NAs monotherapy group Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK) NCT03792919Phase 41 site📍 Hong Kong Humanity & Health Medical Group Limited · Tests: Stop current treatment (anti-HBV neucleos(t)ides), Keep current treatment (anti-HBV neucleos(t)ides) Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) NCT06277037n/a18 sites📍 San Diego📍 Miami📍 Hillsborough Arbutus Biopharma Corporation · Tests: Non-interventional ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis B (CHB) NCT07741461Phase 11 site📍 Shanghai Xiamen Amoytop Biotech Co., Ltd. · Tests: ACT201 Injection, ACT201 Injection Placebo Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B NCT06671093Phase 13 sites📍 Hong Kong📍 Chisinau📍 Auckland Tune Therapeutics, Inc. · Tests: Tune-401 Research on Clinical Recovery and Maintenance Strategies for CHB NCT06803368NA1 site📍 Beijing Beijing Municipal Administration of Hospitals · Tests: baseline anti-HBs titer Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study NCT07079150n/a2 sites📍 Xi'an📍 Xi'an First Affiliated Hospital Xi'an Jiaotong University · Tests: Peg IFN-α-2b A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants NCT07511218Phase 12 sites📍 Ch’ang-ch’un📍 Hangzhou Ausper Biopharma Co., Ltd. · Tests: AHB-171 Injection, Placebo, Nucleos(t)ide Analogue (NA) A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) NCT07137910Phase 212 sites📍 Beijing📍 Jilin City📍 Chongqing Ausper Biopharma Co., Ltd. · Tests: AHB-137, NA therapy Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD NCT05766449n/a1 site📍 Nanjing The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection NCT07146100n/a37 sites📍 Hefei📍 Beijing📍 Chongqing Ausper Biopharma Co., Ltd. To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment NCT07090759Phase 31 site📍 Hangzhou Fujian Akeylink Biotechnology Co., Ltd. · Tests: GST-HG141, GST-HG141 Placebo Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease NCT02863757n/a1 site📍 Hong Kong Humanity and Health Research Centre A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs NCT07069569Phase 214 sites📍 Beijing📍 Chongqing📍 Fuzhou Ausper Biopharma Co., Ltd. · Tests: AHB-137, Peg-IFN, Hepatitis B Vaccine SA1211 Injection Phase 1 Study NCT07275918Phase 11 site📍 Changchun Suzhou Siran Biotechnology Co.,Ltd. · Tests: SA1211 injection, SA1211 injection placebo Study of AHB-171 in Chronic Hepatitis B Participants NCT07630727Phase 210 sites📍 Beijing📍 Chongqing📍 Xiamen Ausper Biopharma Co., Ltd. · Tests: AHB-171 Injection A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease. NCT05255978n/a1 site📍 Wuhan Qin Ning Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation NCT06853886NA3 sites📍 Limoges📍 Limoges📍 Lyon University Hospital, Limoges · Tests: blood sample HBV patient, blood sample healthy volunteers A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B NCT07200193Phase 1, Phase 24 sites📍 Lyon📍 Hong Kong📍 Auckland nChroma Bio · Tests: CRMA-1001 Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region NCT07370207Phase 210 sites📍 Fitzroy📍 Hong Kong📍 Musashino AusperBio Therapeutics Inc. · Tests: AHB-137 Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase NCT05661786n/a5 sites📍 Changzhou📍 Huai'an📍 Nanjing The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… · Tests: Observation, Antiviral treatment Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions NCT07654283Phase 210 sites📍 Palo Alto📍 Baltimore📍 New York AusperBio Therapeutics Inc. · Tests: AHB-137 Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women NCT05853718Phase 41 site📍 Hangzhou First People's Hospital of Hangzhou · Tests: Tenofovir Alafenamide Tablets

🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy